Striving for Clinical Remission in Rheumatoid Arthritis
Sponsored By AbbVie Medical Affairs
Aug 01, 2020
TNF inhibitor
In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include:
SELECT-CHOICE study. ABA vs. UPA in…
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Long Delays in Denosumab Increase Fracture Risk (SAT0453). A UK population based study looked at risk of fracture in adults…
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Voclosporin Effective in Lupus Nephritis (OP0277). Voclosporin is a calcineurin inhibitor that has performed well in an earlier…
Updated EULAR Recommendations for RA Management
Dr. Kathryn Dao from EULAR2020 Virtual Conference
Imaging and Remission Axial Spondyloarthritis
Dr. Olga Petryna from EULAR2020 Virtual Conference
OP0079 - what MRI findings are most predictive in AxSpa
OP0314 - Drug free remission in AxSpA
Dr. Rachel Tate uptoTate
1 month 4 weeks ago
Study in Norway reveals that the majority of the women w/ SpA were not treated with TNF inhibitors before or during pregnancy. Few on TNFi were continued on tx during pregnancy. #EULAR2020 @RheumNow https://t.co/t7B6pASeWQ https://t.co/BwU6RF5Qkn
Dr. Rachel Tate uptoTate
1 month 4 weeks ago
Switching TNFi to VDZ in pts IBD-related SpA associated w/ articular exacerbation of SpA in 1 out of 4 patients within the first 5 months. New-onset MEM is also observed in up to 15% of patients with IBD treated with VDZ. #EULAR2020 @RheumNow https://t.co/ZVjZC7hvxs https://t.co/d1RT3GzB2b
k dao KDAO2011
1 month 4 weeks ago
#EULAR2020 Recc for irAEs w/ICI:
1. GC's ok, goal<10 mg/d, any csDMARD, bDMARD (TNFi/IL-6),🚫ABT xcept life-threatening myositis
2. Myositis beware bulbar signs: dysphagia, dysarthria, dysphonia: stop ICIs,⬆️GC, IVIG/PE
3. Don't test autoAbs b/f ICI Rx
https://t.co/P5jDgnjK94
Therapeutic Update
How do you measure remission in your patients with RA? There are multiple composite measures that can be reliably utilized in clinical practice to assess disease activity and remission. This article highlights these measures and how treatment with upadacitinib, with or without MTX, was assessed across multiple measures of remission in the SELECT program.
Read Post
Featured Video
Images from EULAR2020
